- Home
- SKIL vs PROK Comparison
SKIL vs PROK Comparison
Compare SKIL & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIL
- PROK
- Stock Information
- Founded
- SKIL 1998
- PROK 2015
- Country
- SKIL United States
- PROK United States
- Employees
- SKIL N/A
- PROK N/A
- Industry
- SKIL Computer Software: Prepackaged Software
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKIL Technology
- PROK Health Care
- Exchange
- SKIL Nasdaq
- PROK Nasdaq
- Market Cap
- SKIL 142.2M
- PROK 126.8M
- IPO Year
- SKIL N/A
- PROK N/A
- Fundamental
- Price
- SKIL $22.07
- PROK $0.79
- Analyst Decision
- SKIL Strong Buy
- PROK Buy
- Analyst Count
- SKIL 1
- PROK 4
- Target Price
- SKIL $50.00
- PROK $5.00
- AVG Volume (30 Days)
- SKIL 37.4K
- PROK 1.1M
- Earning Date
- SKIL 04-14-2025
- PROK 05-09-2025
- Dividend Yield
- SKIL N/A
- PROK N/A
- EPS Growth
- SKIL N/A
- PROK N/A
- EPS
- SKIL N/A
- PROK N/A
- Revenue
- SKIL $530,994,000.00
- PROK $76,000.00
- Revenue This Year
- SKIL $4.49
- PROK N/A
- Revenue Next Year
- SKIL $6.77
- PROK N/A
- P/E Ratio
- SKIL N/A
- PROK N/A
- Revenue Growth
- SKIL N/A
- PROK N/A
- 52 Week Low
- SKIL $5.09
- PROK $0.46
- 52 Week High
- SKIL $34.43
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- SKIL 56.77
- PROK 45.47
- Support Level
- SKIL $16.71
- PROK $0.65
- Resistance Level
- SKIL $22.31
- PROK $1.18
- Average True Range (ATR)
- SKIL 1.75
- PROK 0.17
- MACD
- SKIL 0.67
- PROK 0.03
- Stochastic Oscillator
- SKIL 97.00
- PROK 45.97
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Content & Platform and Instructor-Led Training. The Content & Platform business engages in the sale, marketing and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer and Compliance. The Instructor-Led Training business offers training solutions covering information technology and business skills for corporations and their employees. The majority of revenue is from the Content & Platform segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.